The QualityStocks Daily Friday, August 20th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(DVCR) $7.7000 +171.13%

CannabisNewsWire(FLGC) $12.6800 +43.93%

MarketClub Analysis(GOVX) $5.7100 +32.79%

The QualityStocks Daily Stock List

Scientific Industries, Inc. (SCND)

QualityStocks, MarketBeat, Zacks, StocksGoneWild, Greenbackers and Epic Stock Picks reported earlier on Scientific Industries, Inc. (SCND), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Scientific Industries, Inc. designs, manufactures, and markets an array of laboratory equipment. The Company is the world leader in vortexing technologies. The Vortex-Genie Family is based upon, and originates from, the original Scientific Industries Vortex Jr. Mixer, manufactured before 1962. Scientific Industries provides benchtop laboratory equipment, customized catalyst research instruments, and bioprocessing systems and products globally. The Company is based in Bohemia, New York.

Scientific Industries is best known as the designer and manufacturer of the world-renowned Vortex-Genie® laboratory vortex mixer and shaker. This is part of a complete line of other Genie™ brand lab products. These products include microplate shakers and mixers, cell disruptor and homogenizers, magnetic stirrers, orbital shakers, rotators, rockers, and incubators.

All Genie™ products are made in the United States in its Bohemia headquarters. The Company’s products are typically used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, chemical companies, and medical device manufacturers.

In 2006, Scientific Industries diversified by acquiring Altamira Instruments. Altamira is a manufacturer of custom catalyst characterization instrumentation and bench-scale micro-reactor systems for industrial and research use globally. Moreover, in 2014, Scientific Industries expanded its benchtop laboratory equipment business with the acquisition of the Torbal product line. This is a highly reputable brand with a similar long history of quality and reliability, therefore adding a laboratory scales and pharmacy pill counters product line.

Furthermore, in 2016, Scientific Bioprocessing, Inc. was relaunched. This is a subsidiary of Scientific Industries. Scientific Bioprocessing specializes in non-invasive pH and DO monitoring in cell cultivation via its patch sensor based technology acquired by Scientific Industries in 2011.

Recently, the company announced acquisition of aquila biolabs GmbH, a privately held German technology developer of smart sensors and state-of-the-art data analytics software for bioprocessing applications under agreed upon terms. The Company believes the acquisition positions the Company to become a leading player in the bioprocessing industry.

Scientific Industries, Inc. (SCND), closed Friday’s trading session at $9, up 50%, on 14,464 volume with 26 trades. The average volume for the last 3 months is 1,200 and the stock's 52-week low/high is $6.00/$11.3400001.

Assembly Biosciences (ASMB)

MarketBeat, Trades Of The Day, TraderPower, StreetInsider, MarketClub Analysis, BUYINS.NET, Zacks, TradersPro, TopPennyStockMovers, The Best Newsletters, StockMarketWatch, QualityStocks, Marketbeat.com, Market FN and Daily Trade Alert reported earlier on Assembly Biosciences (ASMB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Assembly Biosciences Inc. (NASDAQ: ASMB) (FRA: V7B1) is a clinical-stage biotechnology firm that is focused on the development of oral therapeutic treatments for treating HBV (hepatitis B virus).

The firm has its headquarters in South San Francisco, California and was incorporated in 2005, on October 7th by Derek A. Small and Uri Lopatin. Prior to its name change in June 2014, the firm was known as Ventrus Biosciences Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry.

The company is party to strategic license agreements with Door Pharmaceuticals LLC and Indiana University Research and Technology Corp. In addition to this, it has collaboration agreements with Arbutus Biopharma Corp., BeiGene Limited and Allergan Pharmaceuticals International Ltd.

The enterprise is developing an orally-delivered microbiome therapeutics platform to treat CDAD and a HBV-cure platform. Its product pipeline comprises of a formulation dubbed ABI-H3733, which is indicated for the treatment of HBV and recently concluded phase 1a clinical trials on the same. It also develops ABI-H2158, which is undergoing a phase 2 clinical trial evaluating its effectiveness in treating a chronic HBV infection; and a formulation known as Vebicorvir, which is also used to treat individuals suffering from chronic HBV infection.

The firm recently reported its financial results for the second quarter of 2021, with its CEO asserting that they were focused on advancing their clinical programs after the nomination of a fourth core inhibitor candidate for a best-in-class-profile. The success of their formulations will benefit not only the patients who suffer from the indications the drugs have been developed to treat, but also its shareholders, and will have a positive effect on the firm’s growth.

Assembly Biosciences (ASMB), closed Friday’s trading session at $3.52, up 1.7341%, on 752,750 volume with 3,850 trades. The average volume for the last 3 months is 1.222M and the stock's 52-week low/high is $3.31999993/$22.7450008.

Nymox Pharmaceutical (NYMX)

Willy Wizard, MarketBeat, Wall Street Resources, MarketClub Analysis, INO.com Market Report, StockOodles, Shah's Insights & Indictments, SmallCapVoice, Money Morning, BUYINS.NET, TraderPower, Total Wealth, InvestorPlace, CustomerService, OTCBB Journal, DrStockPick, TopPennyStockMovers, SmarTrend Newsletters, Editor, PennyToBuck, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, PennyOmega, Promotion Stock Secrets, Schaeffer's, StockHotTips, Greenbackers, Wall Street Mover, TradersPro, StocksImpossible, StockMarketWatch, Stock Market Watch, Daily Market Beat, Stock Beast, PennyTrader Publisher, First Penny Picks, Penny Detectives, Hit and Run Candle Sticks, Short Term Wealth, Jason Bond, Power Profit Trades, Barchart and SmallCapInvestor reported earlier on Nymox Pharmaceutical (NYMX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (FRA: NYM) is a biopharmaceutical firm that is engaged in researching and developing medications for the aging population.

The firm has its headquarters in Nassau, the Bahamas and was incorporated in 1995, on May 30th by Paul Averback. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry.

The company generates most of its revenue from sales in the U.S. Its subsidiaries include Serex Inc., which carries out the research, development and manufacture of its TobacAlert and NicAlert products; and Nymox Corp., which carries out research and development. The company serves consumers in Europe, the U.S. and Canada, as well as internationally.

The enterprise’s pipeline consists of NX-1207 (Fexapotide Triflutate), which is in a preclinical program for hepatocellular carcinoma and is also undergoing phase 2 clinical trials evaluating its effectiveness in treating localized prostate cancer (low grade). The candidate has also concluded phase 3 clinical trials which focused on benign prostatic hyperplasia. The enterprise is also involved in the development and marketing of TobacAlert and NicAlert test stripes, which use saliva or urine to detect the use of products with tobacco. Additionally, it provides a urine assay dubbed AlzheimAlert, which assists physicians in diagnosing Alzheimer’s disease.

The firm is set to file for marketing approval for its NX-1207 candidate. The success of this formulation will not only bring in additional revenue into the firm but also encourage more investments into the firm, which will have a positive effect on its growth.

Nymox Pharmaceutical (NYMX), closed Friday’s trading session at $1.94, up 8.3799%, on 240,961 volume with 592 trades. The average volume for the last 3 months is 448,503 and the stock's 52-week low/high is $1.25150001/$3.50.

Cypress Environmental Partners (CELP)

MarketBeat, Investing Daily, The Wealth Report, StreetInsider, Marketbeat.com, Daily Trade Alert, StockMarketWatch, Investiv, Zacks, Trading Concepts, Market Intelligence Center Alert, InvestorPlace, Investing Futures and Barchart reported earlier on Cypress Environmental Partners (CELP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cypress Environmental Partners LP (NYSE: CELP) is an environmental services firm that is engaged in the provision of integrity, independent inspection and support services.

The firm has its headquarters in Tulsa, Oklahoma and was incorporated in March 2012 by Charles C. Stephenson Jr. and Peter C. Boylan III. Prior to its name change in March 2020, the firm was known as Cypress Energy Partners L.P. It mainly serves clients in North America and operates as a subsidiary of Cypress Energy Holdings LLC.

The company operates through the Environmental services, Pipeline and process services and Inspection services segments. The environmental segment operates and owns nine water treatment facilities in North Dakota’s Bakken shale region. It provides separation, recovery, treatment and disposal of waste by-products generated throughout the lifecycle of a natural gas and oil well, to protect drinking water and the environment. The pipeline segment is engaged in the provision of records retention and test documentation services, as well as drying, nitrogen purging, caliper runs, dehydration, filling, flushing, pigging, pumping, water transfer and recycling, chemical cleaning and hydrostatic testing services. On the other hand, the inspection segment provides inspection and integrity services for infrastructure assets like distribution systems, gathering systems and midstream pipelines. In addition to this, it also offers services like supervising 3rd party contractors, gathering data, surveys, pig tracking and non-destructive examination.

The enterprise is focused on long-term diversification efforts to provide its inspection services to other industries. Achieving this will extend the enterprise’s consumer reach significantly, which will bring in additional revenue as well as investors into the firm, which will boost its growth.

Cypress Environmental Partners (CELP), closed Friday’s trading session at $1.3193, off by 2.9926%, on 36,589 volume with 217 trades. The average volume for the last 3 months is 37,204 and the stock's 52-week low/high is $1.30999994/$3.85999989.

Cardiol Therapeutics (CRDL)

We reported earlier on Cardiol Therapeutics (CRDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSE: CRDL) (FRA: CT9) is a clinical-stage biotechnology firm that is engaged in the research and development of anti-inflammatory cannabidiol therapies for treating cardiovascular ailments.

The firm has its headquarters in Oakville, Canada and was incorporated in 2017, on January 19th by Anthony Bolton, Eldon Smith and David Elsley. It operates as part of the pharmaceutical and medicine manufacturing industry, under the health care sector, in the biotech and pharma sub-industry.

The company uses its expertise in pharmaceutical cannabinoids to develop proprietary formulations for commercial development in various medical markets. It also develops nanotechnology that boosts pharmacokinetics, facilitates drug accumulation in a failing heart and allows for the distribution of water insoluble medications in an individual’s blood circulation.

The enterprise’s pipeline is made up of a subcutaneous formulation of cannabidiol which helps achieve higher bioavailability for the treatment of chronic heart failure; and a cannabidiol oral formulation dubbed CardiolRx, indicated for the treatment of coronavirus patients in hospitalization who have a history of risk factors for cardiovascular disease. The high concentration formulation recently concluded phase 1 clinical trials testing its effectiveness in treating acute myocarditis. The enterprise also has an immunotherapeutics program that is focused on developing a cancer immunotherapeutic in combination with cannabinoids, for the treatment of glioblastoma multiforme.

The firm’s CardiolRx formulation; which has been developed for hospitalized coronavirus patients with risk factors or a history of cardiovascular disease, received IND approval from the FDA. This move builds confidence in the formulation and brings it one step closer to new drug application and commercialization, which may bring in move investments into the firm and boost its growth.

Cardiol Therapeutics (CRDL), closed Friday’s trading session at $2.8955, up 2.3145%, on 122,028 volume with 579 trades. The average volume for the last 3 months is 66,835 and the stock's 52-week low/high is $1.53999996/$4.19000005.

Protalix BioTherapeutics (PLX)

Greenbackers, StockMarketWatch, Zacks, MarketDNA, MarketBeat, BUYINS.NET, The Street, StreetInsider, Wealth Insider Alert, Barchart, QualityStocks, Momentum Trades, Investopedia, Insider Wealth Alert, Hit and Run Candle Sticks, Investors Alley, PoliticsAndMyPortfolio.com, SmarTrend Newsletters, Stock Market Watch, Streetwise Reports, The Online Investor, TopPennyStockMovers, TradersPro, Trading Markets, Wall Street Mover and ShazamStocks reported earlier on Protalix BioTherapeutics (PLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Protalix BioTherapeutics Inc. (NYSE American: PLX) (TLV: PLX) (FRA: PBDA) is a biopharmaceutical firm that is engaged in developing and commercializing recombinant therapeutic proteins.

The firm has its headquarters in Karmiel, Israel and was incorporated in 1993 by Yoseph Shaaltiel. It operates as part of the pharmaceutical and medicine manufacturing industry, in the biotech and pharma sub-industry, under the health care sector.

The company develops the proteins based on its ProCellEx plant cell-based protein expression system. It is party to partnerships and agreements with Chiesi Farmaceutici, Fiocruz and Pfizer. The company serves consumers in Brazil and the rest of Latin America, Israel and internationally.

The enterprise’s product pipeline is made up of a plant cell-expressed PEGylated recombinant human deoxyribonuclease I candidate dubbed PRX-119, developed to treat NETs-related ailments; a plant cell-expressed recombinant PECylated Uricase dubbed PRX-115, developed to treat gout; a plant cell recombinant form of human DNase I known as PRX-110, which has concluded phase 2a clinical trials evaluating its efficacy in treating cystic fibrosis. The enterprise also develops a therapeutic protein candidate dubbed PRX-102, which is undergoing a phase 3 clinical trial testing its effectiveness in treating Fabry diseases. In addition to this, it is involved in the provision and sale of Elelyso (taliglucerase-alfa) in Brazil, which has been developed to treat Gaucher disease.

The company recently released its second quarter financial results, with its CEO noting that they were focused on strengthening their balance sheet by entering into definitive agreements. This may bring in more investors into the firm, which would be good for the company’s growth.

Protalix BioTherapeutics (PLX), closed Friday’s trading session at $1.34, up 2.2901%, on 240,354 volume with 828 trades. The average volume for the last 3 months is 1.714M and the stock's 52-week low/high is $1.29999995/$7.01999998.

GeoVax Labs (GOVX)

Wall Street Resources, IRGnews Alert, Standout Stocks, QualityStocks, MarketBeat, MarketClub Analysis, Stockpalooza, Stock Stars, Stock News Now, SmallCapVoice, SmallCapStockPlays, Penny Performers, InvestorPlace, BUYINS.NET, HotOTC, FeedBlitz, Daily Market Beat, CoolPennyStocks, DrStockPick, M2 Communications, PennyTrader.com, PoliticsAndMyPortfolio, ProActive Capital, Wall Street Mover and PennyOmega reported earlier on GeoVax Labs (GOVX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GeoVax Labs Inc. (NASDAQ: GOVX) (FRA: E8L) is a clinical stage biotechnology firm which is engaged in the development, manufacture, testing, licensing and commercialization of human vaccines that prevent and fight ailments caused by HIV-1 and other infectious agents.

The firm operates as part of the biotechnology research services industry and has its headquarters in Smyrna, Georgia. The company was founded in 1988 by Donald G. Hildebrand and Harriet Latham Robinson.

This firm is party to partnership and collaboration agreements with Leidos Inc., the University of California, the Geneva Foundation, Viamune Inc., American Gene Technologies International Inc., the Burnet Institute, the Scripps Research Institute, the University of Maryland Institute of Human Virology, University of Texas Medical Branch, Georgia State University Research Foundation, University of Pittsburgh, Emory University, U.S. Naval Research Laboratory, U.S. Army Research Institute of Infectious Disease, U.S. Department of Defense, the CDC, the HIV Vaccines Trial Network and the National Institute of Allergy and Infectious Diseases of the NIH.

The company is currently developing preventive vaccines against malaria, Zika virus, HIV and the coronavirus as well as hemorrhagic fever viruses like Lassa, Marburg and Ebola; and therapeutic vaccines for chronic Hepatitis B infections and HIV. Additionally, the firm is developing immunotherapies for solid tumor cancers.

This biotechnology firm is at the forefront of forward-thinking vaccine science. Its clinical success has improved its financial position as well its capital structure, which allows it secure long-term funding. Many expect the company to reach numerous vaccine development milestones over the next year, which will benefit both the firm and its shareholders.

GeoVax Labs (GOVX), closed Friday’s trading session at $5.71, up 32.7907%, on 103,636,313 volume with 429,690 trades. The average volume for the last 3 months is 2.413M and the stock's 52-week low/high is $0.25/$8.71000003.

Net Savings Link (NSAV)

Investor Development Group, QualityStocks, Real Pennies, TheMicrocapNews, Stockgoodies, SmallCapVoice and PennyTrader Publisher reported earlier on Net Savings Link (NSAV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Net Savings Link Inc. (OTC: NSAV) is an integrated technology firm that offers turnkey technological solutions to the legal medical marijuana and hemp industries as well as other areas of the medical industry.

The firm provides its services in the United States and has its headquarters in Cresco, Pennsylvania. Net Savings Link Inc. was established on February 21, 2007.

Net Savings Link Inc. operates through the Global Distribution Corporation, which is a subsidiary it owns. Through it, the firm markets and distributes natural remedies, wellness and supplement products. The firm also offers health and wellness products, including probiotics, mineral and vitamin supplements as well as other nutraceuticals health supplements, under its Nutra Horizon brand name.

Net Savings Link Inc. is also focused on providing various services which include e-commerce and software solutions. Additionally, it provides information technology, patents and trademarks, advisory services and financial services, among others. Net Savings Link Inc. also provides hemp based beer under the brand names Angry Tiger Beer and Tiger Hemp Beer.

Net Savings Link Inc. recently announced that it had acquired a major 25% stake in SBCDF Investment Inc., which is scheduled to launch its STUX product soon. The token; SBC Token Unix X, will be marketed through all major social channels like Medium, Twitter, Telegram, Discord and Reddit. Given that SBC is a force to reckon with not only on Wall Street but also across the globe, NSAV is in for an exciting and fruitful era, which will help the company grow and avail various benefits to its shareholders.

Net Savings Link (NSAV), closed Friday’s trading session at $0.0306, up 34.2105%, on 106,546,006 volume with 2,211 trades. The average volume for the last 3 months is 103.37M and the stock's 52-week low/high is $0.000000999/$0.149299994.

Pacific Ventures Group, Inc. (PACV)

MarketBeat, PennyPickAlerts, WePickPennyStocks, FOX Penny Stocks, Super Hot Penny Stocks, Joe Penny Stocks, SixFigureStockPicks, RisingPennyStocks, QualityStocks, Winning Penny Stock Picks, Penny Stock Pick Alert, Fortune Stock Alerts, Liquid Tycoon, LiquidTycoon, Penny Stock Circle, Penny Stock MoneyTrain, 1-2-3 Stock Alerts, PennyStockMoneyTrain, PennyStockPickReport, Real Pennies, StockMarketQuote.us, Super Nova Stock Picks, SuperNovaStockPicks and Penny Stock Pick Report reported earlier on Pacific Ventures Group, Inc. (PACV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Based in Los Angeles, California, Pacific Ventures Group, Inc. is a food and beverage holding company. It specializes in the distribution of consumer food, beverage, as well as alcohol-related products. Its companies include SnoBar, Seaport Meat Company, and San Diego Farmers Outlet. Pacific Ventures Group lists on the OTC Markets.

By way of its subsidiaries, the Company produces, sells, and distributes alcohol-infused ice creams and ice-pops. Pacific Ventures sells its alcohol-infused ice-pops and ice creams under the SnoBar brand name.

Additionally, the Company is involved in the sale and lease of freezers, and also the provision of marketing services. Pacific Ventures is also involved in the supply of fresh and specialty produce, and food products to restaurants, hotels, clubs and bars, resorts, food trucks, and caterers.

SnoBar Frozen Cocktails is Alcohol Infused Ice Cream and Ice Pops. They are made with all natural ingredients and premium alcohol with a full cocktail in every serving. Seaport Meat Company manufactures custom processed beef, pork, chicken, lamb, veal, and seafood. San Diego Farmers Outlet is San Diego's premier supplier of affordable fresh fruits and vegetables and specialty groceries for retail customers and wholesale restaurants.

Pacific Ventures Group, Inc. (PACV), closed Friday’s trading session at $0.3999, up 37.8966%, on 30,041 volume with 16 trades. The average volume for the last 3 months is 15,795 and the stock's 52-week low/high is $0.200100004/$1.30999994.

Rapid Therapeutic Science Laboratories, Inc. (RTSL)

OTC Stock Review and QualityStocks reported earlier on Rapid Therapeutic Science Laboratories, Inc. (RTSL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rapid Therapeutic Science Laboratories, Inc. is an aerosol manufacturing and marketing company centered on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver cannabinoid compounds, including CBD, CBG, and CBN. It has developed and perfected a new method of formulating and manufacturing pressurized metered dose inhalers (pMDI), which contain and properly aerosolize proprietary formulae comprising one or more cannabinoid compounds.

The Company previously went by the name Holly Brothers Pictures, Inc. It changed its name to Rapid Therapeutic Science Laboratories, Inc. in January of this year. Incorporated in 2013, Rapid Therapeutic Science Laboratories is headquartered in Dallas, Texas. The Company lists on the OTC Markets.

Rapid Therapeutic Science Laboratories’ Rxoid™ and nhāler product lines are manufactured in compliance with Good Manufacturing Practices (GMP), on FDA-listed equipment. MDIs are a safe and technically superior replacement for vape pens, mods, and all-in-one products because they use no heat, function perfectly without using dangerous ingredients, and deliver a 98 percent bioavailable dose of CBD and/or cannabinoids directly to the systemic blood stream. This allows the Company to manufacture a scientifically sound and superior alternative to all other cannabinoid vaping systems in a market estimated to be $5 billion in yearly sales.

The Company’s products sell directly to pharmacies, physicians, and other healthcare providers who treat GAD, PTSD and other stress and anxiety disorders. nhāler can be purchased online and Rapid Therapeutic also produces white label products for select commercial clients.

Furthermore, the Company is entering into the medical grade isolate manufacturing space. It will manufacture CBD, CBG, CBN, and diverse other minor cannabinoids and terpenes under proprietary processes as it increases its ever growing list of formulas for support of different treatment regiments that physicians and health care providers are starting to recommend in combination with more traditional mainstream medications.

Rapid Therapeutic Science Laboratories, Inc. (RTSL), closed Friday’s trading session at $0.34, up 32.7866%, on 21,537 volume with 30 trades. The average volume for the last 3 months is 10,026 and the stock's 52-week low/high is $0.140100002/$1.44000005.

H-CYTE, Inc. (HCYT)

StockOnion, QualityStocks, Profitable Trader Authority, Planet Penny Stocks, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter, HotOTC and Buzz Stocks reported earlier on H-CYTE, Inc. (HCYT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

H-CYTE, Inc. is a medical biosciences company based in Tampa, Florida. It develops and implements innovative treatment options in regenerative medicine to help manage chronic obstructive pulmonary disease (COPD) and other debilitating lung diseases. Its concentration is on helping people live fuller lives by way of medical technology and solutions. H-CYTE owns and manages Lung Health Institute and DenerveX® System, two innovative health care brands. The Company’s shares trade on the OTC Markets’ OTCQB.

Regarding Biomedical Services, H-CYTE manages Lung Health Institute. Lung Health Institute is a leader in regenerative medicine. It specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases. Lung Health Institute states that it may be able to those who have COPD, Emphysema, Bronchiectasis, Chronic Bronchitis, Interstitial Lung Disease, and Pneumoconiosis.

Lung Health Institute is located in Tampa, Florida; Scottsdale, Arizona; Dallas, Texas; Pittsburgh, Pennsylvania, and Nashville, Tennessee. Results have shown that 85 percent of Lung Health Institute’s COPD patients report an improvement in their quality of life three months after treatment.

The DenerveX ® System is H-CYTE’s first product. It is intended to provide long-lasting relief from pain associated with Facet Joint Syndrome. The DenerveX® system uses Rotacapsulation™ to deliver high heat and capsular tissue shaving in a posterior capsulectomy procedure, which treats the posterior synovial capsule; targets the facet joint nerve receptors, and terminates the nerve.

The DenerveX® System is a device that is inserted into the facet joint through a small incision during the procedure. This System uses heat and light tissue scraping action on the back of the facet joint to disrupt pain signals. Patients typically recover from the procedure and are back to their everyday activities within two weeks. Currently, this procedure is not available in the United States. Fundamentally, the DenerveX® System is a non-drug alternative system, which allows people with chronic back pain from facet joint syndrome get back to an active lifestyle.

H-CYTE, Inc. (HCYT), closed Friday’s trading session at $0.0388, up 38.5714%, on 568,536 volume with 40 trades. The average volume for the last 3 months is 456,757 and the stock's 52-week low/high is $0.006/$0.990000009.

Diversicare Healthcare Services, Inc. (DVCR)

QualityStocks, StreetInsider, StockOodles, Marketbeat.com, MarketBeat, Wealthpire Inc. and SmarTrend Newsletters reported earlier on Diversicare Healthcare Services, Inc. (DVCR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Diversicare Healthcare Services, Inc. provides long-term care services to patients in 62 skilled nursing and senior housing centers containing 7,329 licensed nursing beds. The OTCQX-listed Company offers Short Stay Rehabilitation, Complex Medical Care, Long Term Care, Memory Care, Hospice Care, as well as Assisted Living. Diversicare has recognition as a first-class provider of post-acute care. It has a comprehensive team trained to administer high quality healthcare that meets patients needs.

Established in 1994, Diversicare Healthcare Services is headquartered in Brentwood, Tennessee. The Company previously went by the name Advocat, Inc. It changed its name to Diversicare Healthcare Services, Inc. in March of 2013.

The Company created and provides therapy powered by Diversicare Therapy Services (DTS). Its services incorporate up-to-date, evidence-based approaches to quality care and treatment in a safe environment. Diversicare Therapy Services’ (DTS’) team of therapists create customized rehabilitation programs based on an individual’s needs.

Diversicare’s physical, occupational, and speech-language pathologists specialize in innovative therapeutic approaches that center on achieving an individual’s best outcomes. In many centers, DTS offers outpatient services provided by the same therapists that assisted one in getting home. DTS has a team of over 1,100 therapists.

Diversicare Healthcare Services, Inc. (DVCR), closed Friday’s trading session at $7.7, up 171.1268%, on 157,173 volume with 312 trades. The average volume for the last 3 months is 3,817 and the stock's 52-week low/high is $1.60000002/$7.90000009.

The QualityStocks Company Corner

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, has reported financial and operating results for the six-month period ending June 30, 2021. Highlights of the report include revenue of more than $2 million with an estimated unaudited gross profit of 60% as compared to revenues of  approximately $100,000 for 2020, operating expenses of $6 million, and a cash balance of approximately $19 million with minimal debt. In addition, an operational highlight for the company included the signing of a major distribution deal with a significant Colombian food distributor Flora Growth expects to generate more than $10 million annually in revenue as well as add an additional 130,000 distribution points across 38 cities in Colombia. To view the full press release, visit https://ibn.fm/wXgPV

  • Flora Growth Corp. is a global cannabis production and distribution company that has created a premium house of brands which supplying its cannabis products for cosmetics, pharmaceuticals, natural wellness, hemp textiles, and food and beverages, with high-quality product at below-standard costs
  • Flora Growth’s primary regulatory licensed operations are in Colombia, where the country’s government recently pursued a new openness in cannabis exports and domestic regulation by lifting bans on the sale and export of dried flower and cannabinoid ingestible products, permitting the sale of custom formulas for medical cannabis, and loosened marketing restrictions
  • Flora Growth has been actively involved in M&A activity, the latest being an announced LOI to acquire 100 percent of luxury cannabis accessories producer Vessel Brand 
  • The company held an earnings call with investors on August 19 to discuss its first half financial results, provide operational updates, and M&A initiatives
  • Flora Growth participated the same day in the SNN Network Summer Virtual Event, presenting information on the company’s activities to a variety of global investors

Global cannabis cultivator and product distributor Flora Growth (NASDAQ: FLGC) is increasing awareness of its position within the international marketplace as well as recent agreements expected to boost its revenues. The company presented information about its operations to investors during the SNN Network Summer Virtual Event on August 19, followed by an earnings call for the first half of the 2021 fiscal year held the same day.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday’s trading session at $12.68, up 43.9274%, on 38,008,961 volume with 187,060 trades. The average volume for the last 3 months is 3.974M and the stock's 52-week low/high is $2.8499999/$21.4500007.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

More than a decade after Tesla Inc.’s (NASDAQ: TSLA) first electric offering, the Tesla Roadster, first hit the roads, the California-based company has become the largest electric vehicle (“EV”) maker as well as the most valuable car company in the world. Despite the relatively high prices of its vehicles, Tesla continues to attract plenty of customers who are more than willing to pay a high premium by combining top-notch modern designs, high performance and innovative technology. Having carved a significant share of the American market for itself, Tesla set out to conquer the largest electric vehicle market in the world — China. The entry of Net Element (NASDAQ: NETE) and other new players into the EV space will take the competition a notch higher, and the customer will ultimately benefit since massive competition tends to bring out the best in all players as they work to attract buyers.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Friday’s trading session at $10.19, up 3.2421%, on 89,640 volume with 2,638 trades. The average volume for the last 3 months is 170,103 and the stock's 52-week low/high is $5.57000017/$19.1499996.

Recent News

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD), an agri-food-tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure food safety of fresh fruits and vegetables, reported that it has filed an updated presentation with the U.S. Securities and Exchange Commission (“SEC”); the report was filed on Aug. 18, 2021. Save Foods focuses on delivering integrated solutions for improved food safety, freshness and quality. The company is committed to working closely with its customers to develop solutions that benefit the entire supply chain and improves the safety and quality of life of both workers and consumers alike. “Communicating Save Foods’ amazing story to our investors is a top priority for us,” said Save Foods CEO David Palach in the press release. “Our newly filed presentation was designed to refine our portrayal to highlight the innovation underlying our holistic treatments and the immediate benefits across all aspects of the supply chain — literally from seed to table.” To view the full press release, visit https://ibn.fm/xlEYT

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Friday’s trading session at $8, up 3.2271%, on 1,855 volume with 21 trades. The average volume for the last 3 months is 7,510 and the stock's 52-week low/high is $1.75/$30.1000003.

Recent News

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to announce that it has received a purchase order for two containers of TAAT™ valued at €720,000 (approximately CAD $1,075,000) from a wholesaler based in London, England who will be the exclusive distributor for TAAT™ in the United Kingdom and Ireland. In a press release dated April 30, 2021 , the Company announced that this same distributor had placed an initial purchase order of €100,000 (approximately CAD $149,000), and subsequently detailed in a May 20, 2021 press release the competitive advantages TAAT™ would have compared to other tobacco brands in the United Kingdom, where tobacco cigarettes must be sold in “plain packaging”, as shown below. The Company’s distributor has also been granted a Confirmation of Registration to the Tobacco and Related Products and Regulatory Competent Authority from Public Health England, providing clearance for TAAT™ to be sold in all of Great Britain (England, Scotland, and Wales).

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

  • Visual – the nearly identical product packaging and enhanced smoke volume
  • Auditory – the “crackling” sound of the base material when it is ignited
  • Smell – when burning, TAAT emits a tobacco-like scent
  • Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
  • Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

  • Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
  • Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
  • Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Friday’s trading session at $3.25, up 2.5269%, on 30,604 volume with 116 trades. The average volume for the last 3 months is 96,046 and the stock's 52-week low/high is $0.620000004/$4.73999977.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer. The participants of the study underwent intravesical therapy together with either mitomycine (“MMC”) or Bacillus Calmette-Guerin (“BCG”) treatments. The objective of the authors of the study was to evaluate the psychosocial issues these study subjects experienced during therapy and what effects those challenges triggered. The field of bladder cancer treatment is evolving rapidly, and the technologies made by companies such as Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) make it easier for oncological surgeons to get a clearer view while performing procedures to remove bladder cancer tissues.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Friday’s trading session at $0.4166, up 18.6895%, on 990 volume with 2 trades. The average volume for the last 3 months is 6,821 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

Hero Technologies Inc. (OTC: HENC)

The QualityStocks Daily Newsletter would like to spotlight Hero Technologies Inc. (OTC: HENC).

In 2003, the U.S. Department of Justice put into motion Operation Pipe Dreams, which led to hundreds of businesses and homes being raided. The $12 million operation, which involved 2,000 law enforcement officers, targeted sellers and makers of cannabis pipes. At the time, selling and making cannabis pipes was a crime, with DEA’s acting administrator John Brown noting that individuals who sold drug paraphernalia were akin to drug dealers. It is great to observe that cannabis legalization has not only allowed companies such as Hero Technologies Inc. (OTC: HENC) to thrive, but other related industries such as cannabis pipe making have also revived around the country.

Hero Technologies Inc. (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (MSO).

The company was founded in 2004 and is headquartered in Dover, Delaware.

Portfolio

The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC.

Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com.

BlackBox Systems and Technologies LLC

BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules.

The system provides a series of key benefits, including:

  • High-pressure nutrient delivery, with no nutrient or PH deficiencies
  • Sterile, 100% nutrient solution
  • Drain to Waste (no reuse of wastewater)
  • Low water usage (1 gallon per plant per day)
  • Constant PH and EC in reservoirs
  • Modular design (1 to 100 pods in any configuration)
  • Innovative proprietary engineering
  • Minimal cleanup
  • Media-less growing, suspended in the air, with no media waste
  • No pesticides

Highly Relaxing LLC

Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort.

Veteran Hemp Co.

Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company.

Market Outlook

The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020.

North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://nnw.fm/snpHh).

The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://nnw.fm/cGxXQ).

With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers.

Management Team

Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors.

Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance.

James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company.

Hero Technologies Inc. (HENC), closed Friday’s trading session at $0.06805, up 11.3748%, on 10,000 volume with 2 trades. The average volume for the last 3 months is 184,520 and the stock's 52-week low/high is $0.0236/$0.317400008.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company, recently released an updated version of its Fan Pass artist livestreaming platform to the app stores on July 24, 2021. Launch of the updates took place exactly on the one-year anniversary of the platform. “The new version offers an all-new UI/UX experience, updated feature sets for the artists and fans, and accelerates the onboarding process and dashboard features. Version 2.0 also includes an updated and refreshed web design,” reads a recent article, which quotes Friendable CEO Robert A. Rositano Jr., commenting on the release. “Our talented development team worked hard to release v2.0 on the anniversary of our original launch. We believe there are more good things to come as artists currently using our platform discover how we’ve improved their ability to monetize livestream events, merchandise and fan subscribers,” he said. “We expect the new features to also reach artists and fans who have not yet experienced our exciting app as we continue to rapidly meet the demands of our growing userbase.” To view the full article, visit https://ibn.fm/GL3Q0

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Friday’s trading session at $0.0085, up 8.9744%, on 25,780,771 volume with 248 trades. The average volume for the last 3 months is 6.206M and the stock's 52-week low/high is $0.00699/$0.097900003.

Recent News

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF)

The QualityStocks Daily Newsletter would like to spotlight Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF).

  • So far in 2021, Mind Cure has embarked on an aggressive plan to strengthen its advisory board and file for new provisional patents for its fully synthetic ibogaine 
  • In January, the company also announced an amended agreement to grow the size of an earlier-announced bought deal financing 
  • This year has also seen the launch of the second stage of manufacturing of Ibogaine for use in psychedelic clinical research 
  • Mind Cure also continues to strengthen its proprietary digital therapeutics technology (“DTx”), iSTRYM
  • All of Mind Cure’s decisions thus far are designed to help the company achieve overall growth and fulfill its vision of easing suffering, increasing productivity, and enhancing mental health 

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) is regarded as a diversified life sciences company that is at the forefront of the mental health industry. The company’s current focus is on developing digital therapeutics, researching psychedelic compounds, and innovating and commercializing new ways to improve and promote healing for individuals dealing with mental health challenges.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.

Technology

Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.

Research

In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

Mind Cure Health Inc. (OTCQB: MCURF), closed Friday’s trading session at $0.2875, up 1.2324%, on 64,269 volume with 35 trades. The average volume for the last 3 months is 248,004 and the stock's 52-week low/high is $0.253500014/$0.858399987.

Recent News

Simply Sonoma Inc.

The QualityStocks Daily Newsletter would like to spotlight Simply Sonoma Inc.

Simply Sonoma is a therapeutic-focused CBD company concentrating on sleep aids, gut health, pain/inflammation, as well as skin and beauty products.  The company has developed plant-based CBD infused products, centered around the agriculture of Sonoma County, California, known for its excellent wines, fruits, and veggies, and now the company aims to put it on the map for exceptional organic plant-based CBD infused, and research- backed formulations. The company is currently in a SEC CF raise to build out its portfolio.  

Simply Sonoma Inc. produces healthy CBD medicinals and beauty products for the environmentally conscious consumer. The company strives to create the best sustainably grown natural medicinal alternative products and is committed to minimizing its carbon footprint by powering operations off-the-grid using solar energy. Simply Sonoma is creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. The company believes in all-natural, organically sun-grown, plant-based medicinals, and it provides consumers with science-based education on CBD for disease and lifestyle needs.

Simply Sonoma is focused on being a leader in the industry for plant-based medicinal health and beauty products and partnering with like-minded organizations. The company strives to develop broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company believes in published, science-based trials and research with regard to its CBD creations.

Simply Sonoma is a different kind of natural company. From seed to sale, it owns or contracts the organic grow, extraction and product formulation operations. The company has been developing products since 2017 based on scientific research and data and has several ready to launch. Its nationally available organic CBD products employ the company’s own proprietary formulations.

For example, the company’s nonalcoholic CBD Pinot Noir beverage uses grapes specially grown for Simply Sonoma and is infused with CBD from the company’s farm. The company expects to generate revenue through national sales of its CBD products via e-commerce, as well as through a variety of chain stores, pharmacies and small businesses throughout the U.S.

Products

Simply Sonoma has three tiers of products:

  1. Organic CBD formulations for consumer medicinal applications.
  2. Organic whole plant extracts of CBD and cannabinoids – providing the whole plant synergistic effect and giving a dose response for a variety of diseases.
  3. Organic extracts paired with traditional over-the-counter functionality, delivering all the benefits of traditional OTC products but the bulk product is organic and plant derived for a more natural healthy approach, minimizing synthetic chemical components and adverse effects.

An example of tier three would be the company’s sleep aid. Current over-the-counter and prescription sleep aids like benzodiazepines, antihistamines and sleeping pills disrupt normal sleep brain patterns including REM, resulting in abnormal sleep. CBD and cannabinoids have efficacy as sleep aids and do not disrupt the normal sleep cycle.

Depending on the application, the company’s products can be delivered via:

  1. Teas
  2. Pills
  3. Inhalers
  4. Skin patches
  5. Gummies
  6. Tablets
  7. Sublingual sprays
  8. Tinctures
  9. Topicals
  10. Juices

Simply Sonoma has partnered with Sonoma Biologics, a premium hemp cultivator that has completed considerable research on the scientific nature of hemp and cannabis, to grow proprietary medicinal strains specifically for the company. Additionally, Simply Sonoma is working with Organic Vineyards on the company’s antioxidant, alcohol free, CBD wine product, as well as its low carb, low sugar Pinot Noir CBD sparkling product. All partner companies are environmentally conscious, solar first and organic-equivalent. Simply Sonoma’s CBD products will contain less than 0.3% of THC.

Market Outlook

Simply Sonoma competes with numerous nondescript CBD companies in the market today. The company feels its major competitive advantage is its scientific staff and product formulation expertise. Simply Sonoma products are focused on four specific health, beauty and lifestyle markets, including sleep aids, joint pain, probiotics and skin health. The Market Data Forecast valued the global sleep aid market at an estimated $175 billion in 2020. The joint pain and anti-inflammatory market is forecast to be worth approximately $41 billion in 2026 by Persistence Market Research. The market for gut health and probiotic products is expected to hit $65 billion by 2023, according to Global Market Insights. Allied Market Research valued the global beauty and skin product market at $380 billion in 2019.

Management Team

Simply Sonoma’s dynamic team has a unique combination of experience that positions them well with the company’s wellness and lifestyle products in the CBD space.

Margaret C. Caracciolo is the CEO of Simply Sonoma. She has spent most of her career in biotechnology, in the areas of clinical research and financials. She has worked for notable biotech companies including Heartport, an innovator of heart therapies. She spent time at Aviron, supporting the development of its innovative nasal flu inoculation product, and Genitope, which created personal gene therapies. She has spent the last 10 years co-managing her family’s farm and vineyard and creating wines and other products from the farm’s organic gardens.

Angela Miller is Vice President of Operations at Simply Sonoma. She has extensive experience in cross line-of-business, global project management, and analysis from inception to post-go-live. She spent more than 20 years working at Oracle Corp. and Sun Microsystems Inc., where she obtained expertise in global products, team building, troubleshooting, and customer relations. She also worked seven years with Schwinn Cycling & Fitness, doing everything in the Fitness Division from project management to marketing and public relations.


Recent News

chart

Streamlytics

The QualityStocks Daily Newsletter would like to spotlight Streamlytics

Streamlytics announces the availability of a broadcast titled, “Third-Party Cookies Are Toast, First-Party Data in Demand as Consumers Clamor for Privacy.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast. To view the full editorial, please visit: https://nnw.fm/gvyVp.

Streamlytics provides ethical, people-powered data, spanning millions of data points from today’s fastest growing communities across the United States. The company unlocks the power of actual data usage, reflective of how people create data today – simultaneously across all types of platforms, not by rigid panels or unethical tracking. By partnering with consumers across the nation, the company has gained unparalleled access to audiences’ and shoppers’ content consumption and purchasing patterns across Netflix, Google, Amazon and more.

Streamlytics’ first consumer facing data acquisition app allows African American consumers to own their data through a data license, value their data with its proprietary data valuation algorithm, and get fairly paid for their data. The result is ethical data transactions and unmatched insight into the decisions that consumers are making across platforms. The company’s data signals are not limited to purchase and content consumption. The breadth of activity spans fitness, health and universal mobility. The current archaic model of consumer data collection across many industries is to use second- or third-party assumptive data based on cookies or affinities, which has a high margin of error causing an enormous amount of waste in financial resources for client organizations. Streamlytics provides clear, accurate, full-spectrum data, delivering the true picture of a coveted consumer group’s activity across their digital footprint.

Since its founding, the company’s mission has been to disrupt the deceptive online data collection processes that have become commonplace. Streamlytics’ drive to prioritize consumer data collection transparency and ethics has led to tremendous growth. The company recently announced it had reached a milestone of more than a quarter-billion data points. Streamlytics’ impressive growth over the past year is largely due to expansion, adding platforms like Apple, Uber, Uber Eats, Postmates and others. The company’s patent-pending data standard, Universal Data Interchange Format (UDIF), powers the unification of cross-platform data sources and formats into a single unified data format. Streamlytics leads the industry in consumer data unification, which is increasingly valuable as companies look to navigate away from third-party data solutions and integrate ethical first-party data across corporate strategy, product innovation, artificial intelligence, marketing and more.

How it Works

Streamlytics unifies consumer data from today’s fastest growing communities across popular platforms spanning over 400 million data points. We ethically unlock the power of actual usage data (directly from the source) and help companies grow by enhancing their 1st-party data strategy across sales, marketing, product, and artificial intelligence.

Streamlytics data enhances existing measurement tools by focusing on density. The company’s approach provides a number of benefits over traditional data sourcing platforms, including:

  • Multidimensional data that offers visibility into consumption behaviors that define decision drivers for consumers
  • An integrated approach that connects a variety of data sources and types to paint the clearest picture of consumer behavior
  • A clear understanding of the consumer, allowing for greater targeting precision that directly impacts the effectiveness of campaigns
  • Ethical sourcing, with consumers directly compensated for their data
  • Protection of all personal identifying information (PII) to ensure privacy and security

The company sells data that has been ethically sourced through a Standard Datastream (a streamlined feed consisting of roughly 22.5 million data points) and a Custom Datastream (a full spectrum feed spanning over 150 million data points). Client organizations subscribe to either datastream, based on the specific audiences they want to reach. Organizations most often use Streamlytics data to enhance their first party data strategies in an effort to increase revenue and sales, refine corporate strategy and enhance machine learning training data to reduce algorithmic bias.

Market Outlook

The global alternative data market was valued at $1.06 billion in 2019 and is expected to grow at a CAGR of 40.1% to reach more than $8 billion by 2027. The global artificial intelligence market was valued at $62.35 billion in 2020 and is expected to achieve a CAGR of 40.2% from 2021 to 2028, according to data from Grand View Research.

Streamlytics believes a new market space is emerging at the intersection of these two thriving industries called ‘Community Driven Data’, which will comprise consumers who have opted in to share their data, and companies that decide using ethically sourced data is better than fines and negative media coverage they could get from continuing to do it the old way.

Streamlytics has positioned itself as the leader of this emerging new market space as consumers increasingly opt out of sharing their data under the current model, and as new laws – like Prop 24, the California Consumer Personal Information initiative passed overwhelmingly by voters in 2020 – mandate greater privacy protections for, and limits on corporate use of, consumer data.

Management Team

Angela Benton is founder and CEO of Streamlytics. She is a pioneer of diversity in the technology industry and of raising awareness around the inequalities that exist in the industry. In 2011, she founded NewME, the first entrepreneurial accelerator globally for minorities. Through her leadership, NewME has accelerated hundreds of entrepreneurs, helping the nascent companies to raise more than $47 million in venture capital funding. That company was acquired in 2018.

Arisha Smith is the Chief Revenue Officer of Streamlytics. An innovator in advertising technology, she has designed growth strategies for businesses leveraging digital, social and mobile platforms for over 20 years. She has held marketing positions at Accenture and Microsoft, as well as at Vibe Media. She earned an MBA from Florida A&M University.


Recent News

chart

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

Red White & Bloom Brands’ (CSE: RWB) (OTCQX: RWBYF) CEO Brad Rogers, in a statement contained in the company’s investor deck presentation, observed that multiple deals, “judiciously purchased and diligently structured,” were coming together to create “the most exciting times in the history of the company.” Rogers further noted that the company was focused on building its key assets and growing the bottom line for its shareholders. To view the full article, visit: https://cnw.fm/XCARz

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Friday’s trading session at $0.686, off by 0.96723%, on 174,721 volume with 156 trades. The average volume for the last 3 months is 276,637 and the stock's 52-week low/high is $0.330000013/$1.64999997.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Pandemic recovery packages for some countries have driven the demand for commodities such as lithium, iron ore and copper even higher. With the demand for metals needed for the clean energy transition and electrification increasing, many companies are thinking about venturing into ocean mining, a virtually unexplored market. Research has shown that the sea floor is abundant in various metals, with reserves estimated to be worth more than $16 trillion. It is interesting to imagine how the operations of mining companies such as Asia Broadband Inc. (OTC: AABB) would radically evolve if these companies had access to the vast resources currently sitting on the seabed.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Friday’s trading session at $0.1201, off by 2.6742%, on 16,627,142 volume with 1,161 trades. The average volume for the last 3 months is 20.009M and the stock's 52-week low/high is $0.0026/$0.658999979.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading